rc 3095 has been researched along with Medulloblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunetto, AL; Brunetto, AT; de Farias, CB; Fratini, L; Ghisleni, EC; Gregianin, LJ; Jaeger, M; Roesler, R; Schwartsmann, G | 1 |
| Abujamra, AL; Brunetto, AL; de Farias, CB; Kapczinski, F; Roesler, R; Schmidt, AL; Schwartsmann, G | 1 |
2 other study(ies) available for rc 3095 and Medulloblastoma
| Article | Year |
|---|---|
Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists.
Topics: Analysis of Variance; Antineoplastic Agents; Apoptosis; Bombesin; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Histone Deacetylase Inhibitors; Humans; Medulloblastoma; Peptide Fragments; Peptides, Cyclic; Receptors, Bombesin | 2016 |
BDNF and PDE4, but not the GRPR, regulate viability of human medulloblastoma cells.
Topics: Animals; Antineoplastic Agents; Bombesin; Brain-Derived Neurotrophic Factor; Cell Survival; Child; Cyclic Nucleotide Phosphodiesterases, Type 4; Gastrin-Releasing Peptide; Gastrointestinal Agents; Humans; Medulloblastoma; Neurotransmitter Agents; Peptide Fragments; Phosphodiesterase Inhibitors; Receptor, trkB; Receptors, Bombesin; Recombinant Proteins; Rolipram | 2010 |